A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.
The findings, published in Cell Host & Microbe, may represent a breakthrough strategy for treating West Nile Virus after virus invasion of the brain and the central nervous system, noted senior author Priti Kumar, M.D., associate professor of infectious disease at Yale School of Medicine.
There are no approved vaccines or effective therapies for West Nile Virus disease, a mosquito-borne condition. While many infected individuals have no symptoms, others — particularly the very young and older adults — can develop severe neurological problems and even die from the disease. The sporadic nature of the disease makes it exceedingly difficult for testing and implementing vaccines, said Kumar.
To investigate a possible new therapy to treat West Nile Virus disease, Kumar and her colleagues focused on a small “interfering” RNA molecule developed in her lab. The RNA acts against multiple mosquito-borne flaviviruses. To direct the RNA to infected cells, they packaged it in a peptide derived from the rabies virus, which is able to enter nerve cells. The final step was to the deliver the therapy through the nose where it could bypass natural barriers protecting the brain.
With this novel approach, the researchers found that the therapy reduced the virus in the brain, preventing harm to nerve cells. The treated mice had a 90% survival rate a few days after infection compared to mice treated with placebo. Significantly, noted the researchers, in the surviving mice, the immune system cleared the virus throughout the body, and also enabled long-term protection against future exposure.
The researchers concluded that the treatment offers both a promising late-stage therapy and lifelong immunity. It “prevents pathology in the brain and gives the mice a chance to develop a robust immune response,” said Kumar.
While the anatomy of the murine nose differs from that of humans, the researchers plan to study the therapy further with the hope it will be broadly applicable. “In translation, it should be an effective strategy for people,” she said.
If that is the case, the intranasal RNA therapy could theoretically be developed for treatment of other mosquito-borne diseases, such as St. Louis encephalitis, Japanese encephalitis, and perhaps Zika, the researchers noted.
The Latest on: RNA therapy
via Google News
The Latest on: RNA therapy
- Talaris Therapeutics, Inc. Announces $100M Series A Financing to Advance Its Novel, Allogeneic Cell Therapy Through Late-Stage Clinical Development on April 18, 2019 at 4:51 am
The Series A funding will be used to advance the company’s proprietary, one-time, allogeneic cell therapy, FCR001, into later-stage clinical development in multiple immune-related indications. The ... […]
- It’s Tough to Find Drugs to Bind to RNA: Arrakis Nabs $75M to Help on April 18, 2019 at 4:02 am
RNA structures are also “floppier,” Gilman ... Obsidian, which is researching how to improve cell therapy by developing ways to control the behavior of these engineered cells, has reached ... […]
- RNA Therapeutics Startup Panorama Medicine Raises $3.7 Million to Accelerate Drug Discovery Using Genomics and Artificial Intelligence on April 16, 2019 at 5:36 am
RNA therapeutics, which involves the modulation ... of the Board of Directors for the American Society of Gene and Cell Therapy. She is a scientific co-founder of Spark Therapeutics and Talee ... […]
- Short tail on RNA makes CRISPR 50X more accurate on April 15, 2019 at 1:00 pm
The approach adds a short tail to the guide RNA that scientists used to identify a sequence of ... able to fit inside of a viral vector to deliver to human cells for gene therapy. But no matter their ... […]
- Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting on April 15, 2019 at 9:26 am
April 15, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, ... […]
- Increasing the specificity of CRISPR systems with engineered RNA secondary structures on April 15, 2019 at 8:11 am
CRISPR (clustered regularly interspaced short palindromic repeat) systems have been broadly adopted for basic science, biotechnology, and gene and cell therapy. In some cases ... Our results ... […]
- Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More on April 12, 2019 at 3:37 am
The gene therapy field continued to attract venture ... invested $800 million in Alnylam as part of an alliance to develop RNA interference medicines for neurological and eye diseases. […]
- Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress™ on April 12, 2019 at 3:00 am
today presented preclinical data at The International Liver Congress™ 2019 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), demonstrating that sustained ... […]
- Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress on April 12, 2019 at 3:00 am
Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA ... […]
via Bing News